CRIXIVAN DIN 02229188
Status: Cancelled Pre Market
Holder: MERCK CANADA INC
Health Canada record
| Active ingredient(s) | INDINAVIR (INDINAVIR SULFATE) 300 MG |
|---|
| Dosage form | Capsule |
|---|
| Route | Oral |
|---|
| Schedule | PRESCRIPTION |
|---|
| Class | Human |
|---|
| ATC | J05AE02 INDINAVIR |
|---|
| Original market date | |
|---|
| Current status date | 01-Nov-2016 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Merck Canada Inc — licence 101380, currently licensed, last inspection rating C (2023-07-17).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing INDINAVIR (INDINAVIR SULFATE)
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02229161 | CRIXIVAN | MERCK CANADA INC | Capsule | INDINAVIR (INDINAVIR SULFATE) 200 MG | Cancelled Post Market |
| 02229196 | CRIXIVAN | MERCK CANADA INC | Capsule | INDINAVIR (INDINAVIR SULFATE) 400 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 7089 | 2005-06-08 | New Drug Submission (NDS) | MANUFACTURER NAME CHANGE |
| 4467 | 1996-09-13 | New Drug Submission (NDS) | |
Request a quote for CRIXIVAN
How to read a Canadian DIN record